Trials / Recruiting
RecruitingNCT06202820
CV CARE: CardioVascular Care in PC Patients
CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)
Detailed description
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. Study procedures including screening for eligibility, treatment visits, questionnaires and surveys, and blood and urine tests. Participation in this research study is expected to last about 6 months. It is expected that about 60-150 people will take part in this study. This study is supported by the National Comprehensive Cancer Network (NCCN) through grant funding provided by Pfizer Myovant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | CV Care Program | Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management. |
Timeline
- Start date
- 2024-01-18
- Primary completion
- 2026-06-01
- Completion
- 2026-12-31
- First posted
- 2024-01-12
- Last updated
- 2025-08-11
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06202820. Inclusion in this directory is not an endorsement.